RATIONALE: Macrophage mannose receptor (MRC) is one of the few molecules known to be involved in lymphocyte trafficking via the lymphatic vessels. In endothelial cells of efferent lymphatics, it binds L-selectin on lymphocytes. In afferent lymphatics, MRC mediates trafficking of both normal and malignant L-selectin-negative cells to the draining lymph nodes. OBJECTIVE: This work was designed to search for additional lymphocyte ligands of MRC to elucidate how lymphocytes migrate into the draining lymph nodes. METHODS AND RESULTS: Using immunoprecipitation and binding studies with natural and recombinant proteins, we show that MRC and CD44 can interact with each other. Fine mapping revealed that the cysteine-rich domain of MRC binds to the chondroitin sulfate side chains of CD44. In vivo homing experiments with MRC- and CD44-deficient mice verified that MRC and CD44 function as a receptor-ligand pair in supporting lymphocyte migration via the afferent lymphatics into the draining lymph nodes. CONCLUSIONS: These data identify a new counter-receptor for MRC and reveal CD44 as a new molecule involved in the poorly understood process of lymphocyte transit via the lymphatic vasculature.
RATIONALE: Macrophage mannose receptor (MRC) is one of the few molecules known to be involved in lymphocyte trafficking via the lymphatic vessels. In endothelial cells of efferent lymphatics, it binds L-selectin on lymphocytes. In afferent lymphatics, MRC mediates trafficking of both normal and malignant L-selectin-negative cells to the draining lymph nodes. OBJECTIVE: This work was designed to search for additional lymphocyte ligands of MRC to elucidate how lymphocytes migrate into the draining lymph nodes. METHODS AND RESULTS: Using immunoprecipitation and binding studies with natural and recombinant proteins, we show that MRC and CD44 can interact with each other. Fine mapping revealed that the cysteine-rich domain of MRC binds to the chondroitin sulfate side chains of CD44. In vivo homing experiments with MRC- and CD44-deficient mice verified that MRC and CD44 function as a receptor-ligand pair in supporting lymphocyte migration via the afferent lymphatics into the draining lymph nodes. CONCLUSIONS: These data identify a new counter-receptor for MRC and reveal CD44 as a new molecule involved in the poorly understood process of lymphocyte transit via the lymphatic vasculature.
Authors: Mylène A Carrascal; Paulo F Severino; M Guadalupe Cabral; Mariana Silva; José Alexandre Ferreira; Fernando Calais; Hermínia Quinto; Cláudia Pen; Dário Ligeiro; Lúcio Lara Santos; Fabio Dall'Olio; Paula A Videira Journal: Mol Oncol Date: 2014-03-06 Impact factor: 6.603
Authors: Hyun Min Jung; Daniel Castranova; Matthew R Swift; Van N Pham; Marina Venero Galanternik; Sumio Isogai; Matthew G Butler; Timothy S Mulligan; Brant M Weinstein Journal: Development Date: 2017-05-15 Impact factor: 6.868
Authors: Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger Journal: J Immunol Date: 2015-07-22 Impact factor: 5.422
Authors: Paul J Marvar; Emma B Hendy; Thomas D Cruise; Dawid Walas; Danielle DeCicco; Rajanikanth Vadigepalli; James S Schwaber; Hidefumi Waki; David Murphy; Julian F R Paton Journal: J Physiol Date: 2016-07-08 Impact factor: 5.182
Authors: Gary A Clawson; Gail L Matters; Ping Xin; Yuka Imamura-Kawasawa; Zhen Du; Diane M Thiboutot; Klaus F Helm; Rogerio I Neves; Thomas Abraham Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240